Summary: Molecules that are limited by a slow onset of action, a suboptimal side-effect profile, or a complicated administration process, may be good candidates for adaptation to a unit- or…
Summary: Lipid-based drug delivery systems have found widespread acceptance for development of drug products containing developability challenged APIs.
Summary: Orphan drugs face obstacles that span from discovery to launch, largely because of small patient populations and limited markets for rare disease therapies.
Summary: Molecules that are limited by a slow onset of action, a suboptimal side-effect profile, or a complicated administration process, may be good candidates for adaptation to a unit- or…
This article discusses how quality by design (QbD) can be built into inhalation product development to ensure a drug and device are safe and effective.
